Cellinfinity is a Yale University spinoff, seed funded company (raised $16 mil, including $3mil from NIH) that has developed novel: 1) in vivo CAR-T vectors and 2) multi-gene edited CAR-Ts against solid tumors. We use unbiased directed evolution and have extensive preclinical data to show that our in vivo vectors selectively target T-cells, produce CAR-Ts in vivo and eliminate solid tumors in mice models. In addition, our novel multi-gene enhanced CAR-Ts (with enhanced potency, infiltration, persistence, etc.) eliminate solid tumors at small fraction of dose needed using conventional CAR-Ts. We have an outstanding management team of CAR-T/gene therapy industry veterans and are seeking Pre-Series A partners/collaborators to help fund IND and clinical trials.